ATAdèle Thomas

Adèle Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adèle Thomas has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial

    by Ilias Goranitis, Leana Bellanca, Amanda J Daley, Adele Thomas, Helen Stokes-Lampard, Andrea K Roalfe, Sue Jowett

    To compare the cost-utility of two exercise interventions relative to a control group for vasomotor menopausal symptoms. Economic evaluation taking a UK National Health Service and Personal Social Services perspective and a societal perspective. Primary care. Peri- and postmenopausal women who have not used hormone therapy in the past 3 months and experience ≥ 5 episodes of vasomotor symptoms daily. An individual and a social support-based exercise intervention were evaluated. The former (Exercise-DVD), aimed to prompt exercise with purpose-designed DVD and written materials, whereas the latter (Exercise-Social support) with community exercise social support groups. Costs and outcomes associated with these interventions were compared to those of a control group, who could only have an exercise consultation. An incremental cost-utility analysis was undertaken using bootstrapping to account for the uncertainty around cost-effectiveness point-estimates. Cost per quality-adjusted life-year (QALY). Data for 261 women were available for analysis. Exercise-DVD was the most expensive and least effective intervention. Exercise-Social support was £52 (CIs: £18 to £86) and £18 (CIs: -£68 to £105) more expensive per woman than the control group at 6 and 12 months post-randomisation and led to 0.006 (CIs: -0.002 to 0.014) and 0.013 (CIs: -0.01 to 0.036) more QALYs, resulting in an incremental cost-effectiveness ratio of £8,940 and £1,413 per QALY gained respectively. Exercise-Social support had 80%-90% probability of being cost-effective in the UK context. A societal perspective of analysis and a complete-case analysis led to similar findings. Exercise-Social support resulted in a small gain in health-related quality of life at a marginal additional cost in a context where broader wellbeing and long-term gains associated with exercise and social participation were not captured. Community exercise social support groups are very likely to be cost-effective in the management of vasomotor menopausal symptoms.


  • The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial

    by Aj Daley, A Thomas, Ak Roalfe, H Stokes‐Lampard, S Coleman, M Rees, M S Hunter, C MacArthur

    Objective: To investigate the effectiveness of exercise as treatment for vasomotor menopausal symptoms.Design: Three‐group randomised controlled trial, two exercise interventions and a control group.Setting: Primary Care, West Midlands UK.Population: Perimenopausal and postmenopausal women experiencing at least five hot flushes/night sweats per day and not taken MHT in previous 3 months were recruited from 23 general practices.Methods: Participants in both exercise interventions groups were offered two face‐to‐face consultations with a physical activity facilitator to support engagement in regular exercise. In addition, one exercise group received a menopause‐specific information DVD and written materials to encourage regular exercise and the other exercise group was offered the opportunity to attend exercise social support groups in their communities. Interventions lasted 6 months.Main outcome measure: The primary outcome was frequency of hot flushes/night sweats at 6‐month up.Results: Two hundred and sixty‐one women were randomised (n = 87 per group). Neither of the exercise intervention groups reported significantly less frequent hot flushes/night sweats per week than controls (exercise‐DVD versus control: −8.9, 95% CI −20.0 to 2.2; exercise‐social support versus control: −5.2, 95% CI −16.7 to 6.3).Conclusions: This trial indicates that exercise is not an effective treatment for hot flushes/night sweats. Contrary to current clinical guidance, women should not be advised that exercise will relieve their vasomotor menopausal symptoms.


  • Exercise for vasomotor menopausal symptoms

    by Amanda Daley, Helen Stokes-Lampard, Adèle Thomas, Christine MacArthur

    Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausal symptoms; hot flushes are the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by hormone therapy (HT), but a marked global decline in its use has resulted from concerns about the risks and benefits of HT. Consequently, many women are seeking alternatives. As large numbers of women are choosing not to take HT, it is increasingly important to identify evidence-based lifestyle modifications that have the potential to reduce vasomotor menopausal symptoms. To examine the effectiveness of any type of exercise intervention in the management of vasomotor symptoms in symptomatic perimenopausal and postmenopausal women. Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility Group Specialised Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley Internet interface), MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid), the Science Citation Index and the Social Science Citation Index (Web of Science), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (Ovid) and SPORTDiscus. Searches include findings up to 3 March 2014. RCTs in which any type of exercise intervention was compared with no treatment/control or other treatments in the management of menopausal vasomotor symptoms in symptomatic perimenopausal/postmenopausal women. Five studies were deemed eligible for inclusion. Two review authors independently selected the studies, and three review authors independently extracted the data. The primary review outcome was vasomotor symptoms, defined as hot flushes and/or night sweats. We combined data to calculate standardised mean differences (SMDs) with 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I(2) statistic. We assessed the overall quality of the evidence for main comparisons using GRADE (Grades of Recommendation, Assessment, Development and Evaluation) methods. We included five RCTs (733 women) comparing exercise with no active treatment, exercise with yoga and exercise with HT. The evidence was of low quality: Limitations in study design were noted, along with inconsistency and imprecision. In the comparison of exercise versus no active treatment (three studies, n = 454 women), no evidence was found of a difference between groups in frequency or intensity of vasomotor symptoms (SMD -0.10, 95% CI -0.33 to 0.13, three RCTs, 454 women, I(2) = 30%, low-quality evidence). Nor was any evidence found of a difference between groups in the frequency or intensity of vasomotor symptoms when exercise was compared with yoga (SMD -0.03, 95% CI -0.45 to 0.38, two studies, n = 279 women, I(2) = 61%, low-quality evidence). It was not possible to include one of the trials in the meta-analyses; this trial compared three groups: exercise plus soy milk, soy milk only and control; results favoured exercise relative to the comparators, but study numbers were small. One trial compared exercise with HT, and the HT group reported significantly fewer flushes in 24 hours than the exercise group (mean difference 5.8, 95% CI 3.17 to 8.43, 14 participants). None of the trials found evidence of a difference between groups with respect to adverse effects, but data were very scanty. Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms. One small study suggested that HT is more effective than exercise. Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.


  • Aerobic exercise as a treatment for vasomotor menopausal symptoms: Randomised controlled trial protocol

    by Amanda J. Daley, Helen Stokes-Lampard, Adèle Thomas, Margaret Rees, Sarah Coleman, Andrea Roalfe, Myra S. Hunter, Christine MacArthur


  • Maternal Exercise and Growth in Breastfed Infants: A Meta-analysis of Randomized Controlled Trials

    by Amanda J. Daley, Adele Thomas, Helen Cooper, Hannah Fitzpatrick, Catherine McDonald, Heather Moore, Rebecca Rooney, Jonathan J. Deeks

    BACKGROUND AND OBJECTIVES: Studies have revealed that women who breastfeed their infants may be reluctant to exercise due to concerns that to do so would adversely affect their breast milk and consequently the growth of their infants. In this review, we seek to systematically review and statistically synthesize evidence from randomized controlled trials (RCTs) that have assessed the effects of maternal exercise on breastfed infant growth (weight gain and gain in length).METHODS: Searches of the following electronic bibliographic databases were performed to identify RCTs: Cochrane Library (CENTRAL), Medline/PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, and SPORT Discus. RCTs that compared any type of exercise intervention with other treatments or no treatment in women exclusively or predominately breastfeeding were eligible for inclusion, as were trials involving exercise as a cointervention. Two authors extracted data from studies independently.RESULTS: Four RCTs (5 comparisons) were included in the meta-analysis of infant weight gain that incorporated 170 participants. In breastfed infants, maternal exercise did not significantly affect infant weight gain (difference in mean weight gain = 18.6 g [95% confidence interval: −113.52 to 150.80, P = .73]). Only 1 trial assessed infant gain in length; no difference between the exercise and control groups was reported. Trials were classified as moderate or good methodological quality (moderate risk of bias).CONCLUSIONS: It appears that mothers can exercise and breastfeed without detriment to the growth of their infants, but this is based on limited evidence, and more research is required before this finding is confirmed.


  • Top Cited Papers

    Cannabidiol displays unexpectedly high potency as an antagonist of CB1and CB2receptor agonistsin vitro

    by A Thomas, G L Baillie, A M Phillips, R K Razdan, R A Ross, R G Pertwee

    Background and purpose: A nonpsychoactive constituent of the cannabis plant, cannabidiol has been demonstrated to have low affinity for both cannabinoid CB1and CB2receptors. We have shown previously that cannabidiol can enhance electrically evoked contractions of the mouse vas deferens, suggestive of inverse agonism. We have also shown that cannabidiol can antagonize cannabinoid receptor agonists in this tissue with a greater potency than we would expect from its poor affinity for cannabinoid receptors. This study aimed to investigate whether these properties of cannabidiol extend to CB1receptors expressed in mouse brain and to human CB2receptors that have been transfected into CHO cells.Experimental approach: The [35S]GTPγS binding assay was used to determine both the efficacy of cannabidiol and the ability of cannabidiol to antagonize cannabinoid receptor agonists (CP55940 andR‐(+)‐WIN55212) at the mouse CB1and the human CB2receptor.Key results: This paper reports firstly that cannabidiol displays inverse agonism at the human CB2receptor. Secondly, we demonstrate that cannabidiol is a high potency antagonist of cannabinoid receptor agonists in mouse brain and in membranes from CHO cells transfected with human CB2receptors.Conclusions and implications: This study has provided the first evidence that cannabidiol can display CB2receptor inverse agonism, an action that appears to be responsible for its antagonism of CP55940 at the human CB2receptor. The ability of cannabidiol to behave as a CB2receptor inverse agonist may contribute to its documented anti‐inflammatory properties.British Journal of Pharmacology(2007)150, 613–623. doi:10.1038/sj.bjp.0707133


  • The psychoactive plant cannabinoid, Δ9‐tetrahydrocannabinol, is antagonized by Δ8‐ and Δ9‐tetrahydrocannabivarin in micein vivo

    by R G Pertwee, A Thomas, L A Stevenson, R A Ross, S A Varvel, A H Lichtman, B R Martin, R K Razdan

    Background and purpose: To follow upin vitroevidence that Δ9‐tetrahydrocannabivarin extracted from cannabis (eΔ9‐THCV) is a CB1receptor antagonist by establishing whether synthetic Δ9‐tetrahydrocannabivarin (O‐4394) and Δ8‐tetrahydrocannabivarin (O‐4395) behave as CB1antagonistsin vivo.Experimental approach: O‐4394 and O‐4395 were compared with eΔ9‐THCV as displacers of [3H]‐CP55940 from specific CB1binding sites on mouse brain membranes and as antagonists of CP55940 in [35S]GTPγS binding assays performed with mouse brain membranes and ofR‐(+)‐WIN55212 in mouse isolated vasa deferentia. Their ability to antagonizein vivoeffects of 3 or 10 mg kg−1(i.v.) Δ9‐tetrahydrocannabinol in mice was then investigated.Key results: O‐4394 and O‐4395 exhibited similar potencies to eΔ9‐THCV as displacers of [3H]‐CP55940 (Ki=46.6 and 64.4 nM, respectively) and as antagonists of CP55940 in the [35S]GTPγS binding assay (apparentKB=82.1 and 125.9 nM, respectively) andR‐(+)‐WIN55212 in the vas deferens (apparentKB=4.8 and 3.9 nM respectively). At i.v. doses of 0.1, 0.3, 1.0 and/or 3 mg kg−1O‐4394 and O‐4395 attenuated Δ9‐tetrahydrocannabinol‐induced anti‐nociception (tail‐flick test) and hypothermia (rectal temperature). O‐4395 but not O‐4394 also antagonized Δ9‐tetrahydrocannabinol‐induced ring immobility. By themselves, O‐4395 and O‐4394 induced ring immobility at 3 or 10 mg kg−1(i.v.) and antinociception at doses above 10 mg kg−1(i.v.). O‐4395 also induced hypothermia at 3 mg kg−1(i.v.) and above.Conclusions and implications: O‐4394 and O‐4395 exhibit similarin vitropotencies to eΔ9‐THCV as CB1receptor ligands and as antagonists of cannabinoid receptor agonists and can antagonize Δ9‐tetrahydrocannabinolin vivo.British Journal of Pharmacology(2007)150, 586–594. doi:10.1038/sj.bjp.0707124


  • Open Access

    In vitroandin vivopharmacology of synthetic olivetol‐ or resorcinol‐derived cannabinoid receptor ligands

    by M G Cascio, T Bisogno, E Palazzo, A Thomas, M van der Stelt, A Brizzi, V de Novellis, I Marabese, R Ross, T van de Doelen, et al.

    Background and purpose: We have previously reported the development of CB‐25 and CB‐52, two ligands of CB1and CB2cannabinoid receptors. We assessed here their functional activity.Experimental approach: The effect of the two compounds on forskolin‐induced cAMP formation in intact cells or GTP‐γ‐S binding to cell membranes, and their action on nociceptionin vivowas determined.Key results: CB‐25 enhanced forskolin‐induced cAMP formation in N18TG2 cells (EC50∼20 nM, max. stimulation=48%), behaving as an inverse CB1agonist, but it stimulated GTP‐γ‐S binding to mouse brain membranes, behaving as a partial CB1agonist (EC50=100 nM, max. stimulation=48%). At human CB1receptors, CB‐25 inhibited cAMP formation in hCB1‐CHO cells (EC50=1600 nM, max. inhibition=68% of CP‐55,940 effect). CB‐52 inhibited forskolin‐induced cAMP formation by N18TG2 cells (IC50=450 nM, max. inhibition=40%) and hCB1‐CHO cells (EC50=2600 nM, max. inhibition=62% of CP‐55,940 effect), and stimulated GTP‐γ‐S binding to mouse brain membranes (EC50=11 nM, max. stimulation∼16%). Both CB‐25 and CB‐52 showed no activity in all assays of CB2‐coupled functional activity and antagonized CP55940‐induced stimulation of GTP‐γ‐S binding to hCB2‐CHO cell membranes.In vivo, both compounds, administered i.p., produced dose‐dependent nociception in the plantar test carried out in healthy rats, and antagonised the anti‐nociceptive effect of i.p. WIN55,212‐2. In the formalin test in mice, however, the compounds counteracted both phases of formalin‐induced nociception.Conclusions and implications: CB‐25 and CB‐52 behavein vitromostly as CB1partial agonists and CB2neutral antagonists, whereas their activityin vivomight depend on the tonic activity of cannabinoid receptors.British Journal of Pharmacology(2006)149, 431–440. doi:10.1038/sj.bjp.0706888


  • First “hybrid” ligands of vanilloid TRPV1 and cannabinoid CB2receptors and non‐polyunsaturated fatty acid‐derived CB2‐selective ligands

    by Giovanni Appendino, Maria Grazia Cascio, Sara Bacchiega, Aniello Schiano Moriello, Alberto Minassi, Adèle Thomas, Ruth Ross, Roger Pertwee, Luciano De Petrocellis, Vincenzo Di Marzo

    12‐Phenylacetyl‐ricinoleoyl‐vanillamide (phenylacetylrinvanil, PhAR, IDN5890), is an ultra‐potent agonist of human vanilloid TRPV1 receptors also endowed with moderate affinity for human cannabinoid CB2receptors. To improve its CB2affinity and temper its potency at TRPV1, the modification of the polar headgroup and the lipophilic 12‐acylgroup of PhAR was pursued. Replacement of the vanillyl headgroup of PhAR with various aromatic or alkyl amino groups decreased activity at TRPV1 receptors, although the dopamine, cyclopropylamine, 1′‐(R)‐ and 1′‐(S)‐methyl‐ethanolamine, and ethanolamine derivatives retained significant potency (EC5031–126 nM). Within these compounds, the 12‐phenylacetylricinoleyl cyclopropylamide and ethanolamide were the strongest ligands at CB2receptors, withKiof 22 and 44 nM, and 14‐ and >20‐fold selectivity over cannabinoid CB1receptors, respectively. The propyl‐ and allyl‐derivatives also exhibited high affinity at CB2receptors (Ki= 40 and 22 nM, with 40 and >80‐fold selectivity over CB1receptors, respectively), but no activity at TRPV1 receptors. The cyclopropyl‐ and allyl‐derivatives behaved as CB2inverse agonists in the GTP‐γ‐S binding assay. Addition ofpara‐methoxy, ‐tert‐butyl or ‐chlorine groups to the 12‐phenylacetyl moiety of PhAR produced compounds that retained full potency at TRPV1 receptors, but with improved selectivity over CB2or CB1receptors. Thus, the manipulation of PhAR led to the development of the first CB2/TRPV1 dual ligands and of an entirely new class of inverse agonists at CB2receptors. Both types of compounds might find application in the treatment of inflammation, and represent new molecular probes to investigate the endocannabinoid–endovanilloid signalling system.